Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.52 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.52 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7324033 | 0.81 | ALDH1A1 (0.54) | ALDH1A1TSHRCARM1PRMT6PRMT8 | |
| SCHEMBL7937668 | 0.80 | CARM1 (0.58) | ALDH1A1TSHRCARM1PRMT6PRMT8 | |
| SCHEMBL29956348 | 0.80 | KDM4E (0.42) | ALDH1A1TSHRUSP2CYP3A4PYCR1 | |
| SCHEMBL19910402 | 0.80 | CYP2D6 (0.48) | MAOAMAOB | |
| Dibemethine SCHEMBL10542007 | 0.79 | ALDH1A1 (0.70) | ALDH1A1TSHRCARM1PRMT6PRMT8 | |
| Dibemethine SCHEMBL276863 | 0.79 | ALDH1A1 (0.70) | ALDH1A1TSHRCARM1PRMT6PRMT8 | |
| SCHEMBL185582 | 0.79 | PYCR1 (0.67) | ALDH1A1TSHRCARM1PRMT6PRMT8 | |
| SCHEMBL1650495 | 0.78 | CA2 (0.47) | ALDH1A1TSHRAOC3KDM4ENPC1 | |
| SCHEMBL16924691 | 0.78 | CHRNB2 (0.67) | ALDH1A1LMNAKDM4E | |
| SCHEMBL9687347 | 0.78 | ALDH1A1 (0.50) | ALDH1A1TSHRCARM1PRMT6PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258316-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-03-25 | — | — | US | claimed |
| US-20220306579-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-29 | — | — | US | claimed |
| EP-2044083-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-08 | — | — | EP | claimed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | claimed |
| WO-2008008912-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| WO-2008008907-A2 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | claimed |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | US | claimed |
| EP-1472216-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Axys Pharmaceuticals (US) | 2004-11-03 | — | — | EP | claimed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | claimed |
| US-12258316-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240327352-A1 | NOVEL PROCESS FOR THE PREPARATION OF 1-(2-{4-[(4-CARBAMOYLPIPERIDIN-1-YL)METHYL]- N-METHYLBENZAMIDO}ETHYL)PIPERIDIN-4-YL N-({1,1'-BIPHENYL}-2-YL)CARBAMATE | MSN LABORATORIES PRIVATE LTD, R&D CENTER (IN) | 2024-10-03 | — | — | US | disclosed |
| CN-117263850-A | Synthesis method of raffinacine | 华中药业股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20220388981-A1 | CRYSTALLINE FORMS OF A BIPHENYL COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2005087736-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050203133-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
| US-20050203131-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2005-09-15 | — | — | US | disclosed |
| US-20050203137-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
| US-20050203138-A1 | Biphenylylaminocarbonyl-amino- or -oxypiperidine derivatives, e.g., biphenyl-2-ylcarbamic acid 1-[2-((4-[(4-hydroxybenzylamino)methyl]benzoyl)methylamino)ethyl]piperidin-4-yl ester; treating bronchodilation, asthma and chronic obstructive pulmonary disease (COPD) | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306579-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | ALDH1A1 1082/4885TSHR 68/4885CARM1 587/4885 |
| US-20050203131-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM3, CHRM1 | ALDH1A1 1207/4885TSHR 92/4885CARM1 793/4885 |
| US-20220388981-A1 | CRYSTALLINE FORMS OF A BIPHENYL COMPOUND | FFAR1, FFAR4, FFAR3 | ALDH1A1 2252/4885TSHR 3505/4885CARM1 3175/4885 |
| US-20050203133-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | ALDH1A1 1082/4885TSHR 68/4885CARM1 587/4885 |
| US-20050203138-A1 | Biphenylylaminocarbonyl-amino- or -oxypiperidine derivatives, e.g., biphenyl-2-ylcarbamic acid 1-[2-((4-[(4-hydroxybenzylamino)methyl]benzoyl)methylamino)ethyl]piperidin-4-yl ester; treating bronchodilation, asthma and chronic obstructive pulmonary disease (COPD) | CHRM1, CHRM2, CHRM3 | ALDH1A1 828/4885TSHR 426/4885CARM1 260/4885 |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | HAVCR2, ZC3HAV1, SARS1 | ALDH1A1 1627/4885TSHR 4537/4885CARM1 1625/4885 |
| US-12258316-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | ALDH1A1 1082/4885TSHR 68/4885CARM1 587/4885 |
| US-20240327352-A1 | NOVEL PROCESS FOR THE PREPARATION OF 1-(2-{4-[(4-CARBAMOYLPIPERIDIN-1-YL)METHYL]- N-METHYLBENZAMIDO}ETHYL)PIPERIDIN-4-YL N-({1,1'-BIPHENYL}-2-YL)CARBAMATE | CYP4B1, CYP1B1, KDM4B | ALDH1A1 250/4885TSHR 2899/4885CARM1 87/4885 |
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | ALDH1A1 1357/4885TSHR 4492/4885CARM1 4190/4885 |
| US-20050203137-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | ALDH1A1 1670/4885TSHR 76/4885CARM1 800/4885 |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | ALDH1A1 1478/4885TSHR 3583/4885CARM1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.